Rostromedial tegmental nucleus

The rostromedial tegmental nucleus (RMTg), also known as the tail of the ventral tegmental area (tVTA), is a GABAergic nucleus which functions as a "master brake" for the midbrain dopamine system. It is poorly differentiated from the rest of the ventral tegmental area (VTA) and possesses robust functional and structural links to the dopamine pathways. Notably, both acute and chronic exposure to psychostimulants have been shown to induce FosB and ΔFosB expression in the RMTg; no other drug type has been shown to induce these proteins in the RMTg.
Inputs.
The RMTg receives incoming projections from the following structures:
Outputs.
GABA projections from the RMTg include:
Clinical significance.
The RMTg plays a "crucial role" in the regulation of dopaminergic neuronal activity in the central nervous system by endogenous opioids and opiate drugs. The GABAergic neurons that project from the RMTg to the midbrain dopaminergic nuclei (i.e., the ventral tegmental area and substantia nigra pars compacta) express μ-opioid receptors. Current evidence suggests that exogenous opiates (e.g., morphine and heroin) excite the dopamine pathways originating in the VTA by activating the μ-opioid receptors in neurons projecting from the RMTg; opioid activation of these neurons leads to disinhibition of the GABAergic brake on dopamine networks. Since RMTg projections to the VTA are the primary inhibitor of the dopaminergic pathways that are implicated in addiction (e.g., the mesolimbic pathway), the RMTg plays a significant role in the development of opiate addictions.
Psychostimulants have been shown to increase expression of the FosB and ΔFosB in the RMTg; the effects of stimulant-induced increases in ΔFosB expression in the RMTg are not known.